55X_ROI_Q1_2026
Oct 14, 5:55 PM
$SLS $IBRX - Don't be Surprised when this rigged SLS
$2.5B Mcap is
$25B /
$125 per share and Climbing,
for the same reason
$MRNA ran from
$20 to
$225 and added
$50B in market value in the days after its Phase 3 Cancer vaccine results were announced.
$ABBV
• Imminent 80th Event PR and GPS P3 Results
• Gps Immunotherapy is getting Fda GREENLIGHT to Treat 50,000 Patients Each year + 100,000 AML patients CURRENTLY in Remission
- 100,000 right out of the GATE.
• The Co Estimated a Minimum of
$300K Revenue Per Patient Year 1.
Indefinite Multi Year Dosing Regime Compounds the Rev for 5+ Years.
-
$28B Total Addressable Market
- Right out of the GATE
Plus 12,500 AML CR2/3 Patients who are Eligible Each Year
... Just this CR2/3 Market is worth
$125 Per Share.
0 replies
